Title for MeetingAbstracts
Alphabetical listing of titles
Anergy and dysfunction of CD4+ and V gamma 2V delta 2+ lymphocytes associated with Mycobacterium bovis BCG-induced disease in SIV-infected monkeys.
Anergy and dysfunction of CD4+ and Vgamma 2Vdelta 2+ lymphocytes associated with Mycobacterium bovis BCG-induced disease in SIV-infected monkeys.
Anergy in intravenous drug users (IVDUs); prevalence, influence of HIV status, sex.
Anergy induction to common antigens due to presentation by MHC class II on HIV-1.
Anergy State of HIV-Specific CD4+ T Cells Detected by Class II Tetramers but Suppressed by Several Stimuli.
Anergy status and CD4 CD29 memory T-cells predict progression to AIDS.
Anergy testing among HIV-negative and positive injection drug users.
Anergy testing: questionable utility in the diagnosis of TB.
Anergy, depletion and epitope mutations: mechanisms of CTL decline during the natural course of HIV-1 infection.
Anger, mood and therapy adherence in HIV infected patients.
Anger: an important psychological measure in HIV disease?
Angiotensin Converting Enzyme Inhibitors Increase Mortality in Bacteremic Infections.
Anidulafungin (ANID) Pharmacokinetic (PK) / Pharmacodynamic (PD) Correlation: Treatment of Esophageal Candidiasis (EC).
Anidulafungin (ANID) vs. Fluconazole (FLU) in Esophageal Candidiasis (EC): a Phase 3, Randomized, Double-Blind, Multicenter Trial.
Anidulafungin Does Not Affect the Metabolism of Cyclosporin by Human Hepatic Microsomes.
Anidulafungin: a Phase 1 Study to Identify the Maximum Tolerated Dose in Healthy Volunteers.
Anidulafungin: Pharmacokinetics (PK) in Subjects with Severe Hepatic Impairment (HI).
Anidulafungin: Pharmacokinetics in Subjects Receiving Hemodialysis.
Anidulafungin: Pharmacokinetics in Subjects with Mild and Moderate Hepatic Impairment.
Anidulafungin: Pharmacokinetics in Subjects with Renal Impairment.
Anidulafungin: Safety and Pharmacokinetics in Subjects Receiving Concomitant Cyclosporine.
Animal model for AIDS immunology, secondary to symptomless infection with Treponema pallidum.
Animal model for anti-viral therapy: effect of AZT treatment on cellular and seric viral loads during early stages of SIVmac251 infection of macaques.
Animal model for pediatric AIDS: pathology in infant rhesus monkeys infected with SIVSMM through maternal transmission.
Animal Model of Human IgG Subclass Deficiency: g3 Gene-Disrupted Mice Deficient in the Dominant IgG Subclass Made to Bacterial Polysaccharides (PS) are More Susceptible to Fatal Pneumococcal(Pn) Sepsis.
Animal model testing of an HIV-1 envelope vaccine candidate from the clinical R5 isolate BX08 using humanized genes and DNA vaccination.
Animal models of pneumocystis carinii pneumonia.
Animation for active community participation for sustainable HIV/AIDS behaviour change.
Ankali project: client evaluation of a program providing volunteer emotional support for people with AIDS.
ANLAIDS: a voluntary association to support AIDS patients: evaluation of problems for a home care system.